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Background: Unambiguous human leukocyte antigen (HLA) typing is important in transplant matching and
disease association studies. High-resolution HLA typing that is not restricted to the peptide-binding region can
decrease HLA allele ambiguities. Cost and technology constraints have hampered high-throughput and efficient
high resolution unambiguous HLA typing. We have developed a method for HLA genotyping that preserves the
very high-resolution that can be obtained by next-generation sequencing (NGS) but also achieves substantially
increased efficiency. Unambiguous HLA-A, B, C and DRB1 genotypes can be determined for 96 individuals in a
single run of the Illumina MiSeq.
Results: Long-range amplification of full-length HLA genes from four loci was performed in separate polymerase
chain reactions (PCR) using primers and PCR conditions that were optimized to reduce co-amplification of other
HLA loci. Amplicons from the four HLA loci of each individual were then pooled and subjected to enzymatic library
generation. All four loci of an individual were then tagged with one unique index combination. This multi-locus
individual tagging (MIT) method combined with NGS enabled the four loci of 96 individuals to be analyzed in a
single 500 cycle sequencing paired-end run of the Illumina-MiSeq. The MIT-NGS method generated sequence reads
from the four loci were then discriminated using commercially available NGS HLA typing software. Comparison of
the MIT-NGS with Sanger sequence-based HLA typing methods showed that all the ambiguities and discordances
between the two methods were due to the accuracy of the MIT-NGS method.
Conclusions: The MIT-NGS method enabled accurate, robust and cost effective simultaneous analyses of four HLA
loci per sample and produced 6 or 8-digit high-resolution unambiguous phased HLA typing data from 96 individuals
in a single NGS run.
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The human leukocyte antigen (HLA) molecules are
encoded by genes located within a 3.6 Mb region on
chromosome 6p21. The defining feature of HLA genes
is their extreme polymorphism (http://www.ebi.ac.uk/
ipd/imgt/hla/stats.html). These genes encode surface
expressed glycoproteins with a peptide-binding region* Correspondence: rthomas@hivresearch.org
1U. S. Military HIV Research Program (MHRP), Walter Reed Army Institute of
Research, 503 Robert Grant Avenue, Silver Spring, MD, USA
2Henry M. Jackson Foundation for the Advancement of Military Medicine,
Bethesda, MD, USA
Full list of author information is available at the end of the article
© 2014 Ehrenberg et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.(PBR) that presents peptides to autologous T lympho-
cytes and NK cells during the immune surveillance
process. HLA molecules thus have a central role in
both innate and adaptive immune responses [1,2] and
exert strong influence on cancer, autoimmunity, infec-
tious diseases, and transplantation [3].
HLA genes contain five to eight exons and range in
length from 4–17 Kb. Due to cost and time constraints
most high-resolution 4-digit HLA genotyping methods
employ sequence-based typing (SBT) or differential probe
hybridization techniques primarily focused on the PBR
consisting of exons 2 and 3 (546 bp total) for class I, andtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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clude the other exons, enhancer or promoter regions, in-
trons, and the untranslated regions (UTR). Variation in
these regions may be functionally important and can influ-
ence HLA transcription rate, gene expression, splice site
variation, mRNA stability, and protein structural integrity
[4-6]. Also importantly, genotyping when limited to the
sequences in PBR may give rise to HLA types that are not
phase-defined or are ambiguous.
HLA typing methods based on whole gene sequences
extending from enhancer/promoter through 3′UTR re-
gions could address phasing and ambiguity problems that
arise due to conventional partial sequencing methods and
potentially identify sequences of functional importance
that may otherwise be overlooked. The advent of next-
generation sequencing (NGS) technologies has facilitated
high-throughput parallel sequencing of the human gen-
ome and made contiguous sequencing of long genes a
reality. Several groups have applied NGS technologies to
genotype the highly polymorphic HLA genes using vari-
ous amplification and library preparation strategies, se-
quencing platforms, and sequence analysis approaches to
greatly enhance sequencing coverage depth and resolve
ambiguities [7-14]. Limitations in these reports include
relatively small sample sizes, non-contiguous amplicons,
partial gene sequencing, multiple PCR for one locus, and
use of laborious library preparation and complex sequence
analysis methods.
Hosomichi et. al. simplified the laboratory component
of NGS HLA typing technology by using a commercial
transposase-based kit for fragmentation and library
preparation of long-range contiguous sequences of indi-
vidual HLA genes, which were then sequenced on the
Illumina MiSeq platform [10]. This method is however
limited to analysis of four HLA loci in 24 individuals per
sequencing run due to their utilization of a unique index
tag for each locus from an individual. Since multiple
HLA loci genotypes are typically required from each in-
dividual we developed a multiplex individual tagging ap-
proach to enable HLA-A, B, C, and DRB1 to be
simultaneously typed in each of the 96 homozygous or
heterozygous individuals per sequencing run. Contigu-
ous highly locus-specific whole gene PCR amplifications
of four HLA loci per individual were pooled and sub-
jected to library construction using the transposase-
based Nextera XT kit (Illumina) and 96 indices. One
unique index combination is used collectively for the
four loci of each individual and not per locus. The 96
separately indexed multiplex samples, each composed of
four loci, are then collectively pooled and sequenced in a
single run on the Illumina MiSeq platform. For each in-
dividual the four loci either homozygous or heterozy-
gous are discriminated using commercially available
NGS HLA typing software. This robust, highly specific,and cost effective approach simultaneously sequences
full-length HLA-A, B, C, and DRB1 loci using multi-
locus individual tagging and NGS (MIT-NGS). As these
four loci are the most polymorphic loci described in the
IMGT/HLA database their genotyping by MIT-NGS
demonstrates the ability of this method to delineate mul-
tiple alleles of very complex loci.
Methods
Samples
Fifteen well-characterized HLA typed control genomic
DNA (gDNA) samples from HLA Reference Panels were
obtained from the International Histocompatibility Work-
ing Group (IHWG) (Research Cell Bank, Fred Hutchinson
Cancer Research Center, Seattle, WA). Additionally, per-
ipheral blood mononuclear cells (PBMCs) from 81 healthy
donors of mainly Asian, Caucasian and African ancestry
enrolled in the U.S. Military HIV Research Program
(MHRP) RV144 and RV229 study protocols were included
in this study. The RV144 study was approved by the
Human Subjects Research Review Board, Ft Detrick,
MD, USA as well as the Thai Ministry of Public Health
Ethical Committee, the Mahidol University IRB, and
the Royal Thai Army IRB. The RV229 protocol was
reviewed and approved by the Walter Reed Army Insti-
tute of Research IRB. All individuals gave informed
consent for participation in this study. Genomic DNA
from the PBMCs was extracted and purified using the
QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA)
according to the manufacturers’ suggestions.
HLA genotyping by Sanger sequence-based typing (SBT)
HLA class I genotyping was performed using the 13th
International Histocompatibility Workshop SBT method
adapted by Lazaro et al. [15]. HLA-DRB1 genotyping
was performed with initial group specific allele amplifi-
cation using primers that were tagged with the M13 se-
quence (Additional files 1 and 2) [16-18]. The DRB1
PCR conditions were modified to use a SYBR Green
assay consisting of 1X Platinum SYBR Green qPCR
Supermix-UDG with ROX (Life Technologies, Carlsbad,
CA), 2 ul of the respective 0.625 or 1.25 uM primer mix,
and 5 ng of gDNA in a total reaction volume of 5 ul.
PCR amplifications were performed in Veriti 384-well
thermal cyclers (Life Technologies) using the following
parameters: 95C, 3 min; 5 cycles of 95C, 5 sec; 65C,
15 sec; 72C, 30 sec; 26 cycles of 95C, 30 sec; 58C,
15 sec; 72C, 30 sec; 5 cycles of 95C, 5 sec; 56C, 30 sec;
72C, 1 min; followed by a 72C, 7 min extension. An
amplified product was detected by dissociation curve
analyses using a 7900HT Fast Real-Time PCR System
with SDS v2.4 software (both Life Technologies) [19] and
purified using 1.8X Agencourt AMPure beads on a Bio-
mek NXp instrument (both Beckman Coulter, Miami, FL).
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and reverse primers using BigDye Terminator cycle se-
quencing v3.1 kits and a 3730xl DNA analyzer (both
Life Technologies). HLA sequences from all four loci
were analyzed using the Assign ATF software v1.0.2.45
(Conexio Genomics, Fremantle, Australia).
Long-range PCR template preparation
Previously described locus specific long-range PCR primers
(Additional file 3) were used to amplify HLA-A, B, and C
genes consisting of 5466, 4609, and 4802 base pairs, re-
spectively [9]. A modified version of the Hosomichi
et al. primers (Additional file 3) was used for HLA-
DRB1 amplification to minimize allelic imbalance and
dropout [10]. Four of the IHWG reference samples
(IHW09021, IHW0924, IHW09056, IHW09381) were
duplicates and were used to evaluate consistency of the
MIT-NGS method across 96-well plates. The original
PCR amplification conditions for all loci were modified.
Briefly HLA-A, B, and C loci were amplified in 10 ul re-
action volumes consisting of 25 ng gDNA, 1X Buffer,
2 mM MgSO4, 200 uM dNTPs (Fermentas, Pittsburgh,
PA), 5% DMSO (Sigma-Aldrich, St. Louis, MO), 200
nM of the respective HLA locus-specific primer mix,
and 0.5 U Platinum Taq HiFi (Life Technologies). The
HLA-DRB1 locus was amplified in 10 ul reaction volumes
consisting of 25 ng gDNA, 1X GXL Buffer, 200 uM
dNTPs, 200 nM of the respective primer mix (Sigma-
Genosys), and 0.25 U PrimeSTAR GXL (Takara Bio
Inc, Japan). PCR cycling parameters are shown in
Additional file 4. To confirm PCR amplification, 1 ul of
each PCR product was screened for the presence of ampli-
con on 1% agarose gels. The remaining product was puri-
fied using Agencourt AMPure beads on a Biomek NXp
instrument (both Beckman Coulter). The purified product
was then quantitated with the Qubit Fluorometric system
(Life Technologies).
Multiplex library preparation and next-generation
sequencing
Each of the four purified HLA amplicons from an indi-
vidual were diluted in a single well of a 96-well plate to
a collective concentration of 0.16 ng/ul. Library con-
struction including simultaneous transposase-mediated
fragmentation and adaptor addition was performed with
the Nextera XT DNA sample preparation kit (Illumina,
San Diego, CA). Briefly multiplex sample wells contain-
ing 3.2 ng (0.8 ng of each amplicon) were dual-indexed,
bead-normalized, and pooled. Four loci from each of the
96 individuals were tagged with an identical individual
specific index pair, and thus 96-paired indices could be
used to tag 768 alleles (96 individuals x 4 loci x 2 alleles).
The resulting pooled sequencing library was diluted in
HT-1/5% Tris–HCl, pH7.5 [20] and sequenced on aMiSeq instrument using the paired-end 500 cycle (2 x
250 bp paired-end) MiSeq Reagent Kit (both Illumina).
Samples with MIT-NGS genotypes that were discord-
ant with the SBT method were repeated by increasing
the DRB1 locus amplicon product input to three-fold
relative to the class I loci to account for the average
three-fold amplicon size difference. Purified HLA ampli-
cons from an individual were diluted in a single well of a
96-well plate to concentrations of 0.16 ng/ul for the
HLA class I loci and 0.48 ng/ul for DRB1. During the li-
brary preparation, multiplex sample wells containing
4.8 ng (0.8 ng of each HLA class I amplicon and 2.4 ng of
the -DRB1 amplicon) were dual-indexed, bead-normalized,
and pooled. Samples were then run on the MiSeq as de-
scribed above.
Data analysis
MiSeq Reporter analysis software (Illumina) generated
FASTQ sequence reads and used a 1.3 Mb reference ex-
tending from HLA-DPB1 through HLA-A of the hg19
build to create BAM alignments. The Integrative Gen-
omics Viewer (IGV) browser was used to independently
review sequence alignments generated by the Miseq Re-
porter [21]. HLA genotyping calls based on exonic se-
quences were made using Omixon Target software v1.7
(Omixon Biocomputing Kft, Budapest, HU). Version 1.8
of the Omixon Target software (Omixon) was used to
reanalyze the HLA locus discordance(s). The software
used reference sequences from the IMGT/HLA database
Release v3.10.0 and v3.15.0. Raw Sequence data was sub-
mitted to the European Nucleotide Archive repository,
(Study Accession number PRJEB7337) and compiled in
the European Molecular Biology Laboratory (EMBL/EBI)
Nucleotide Sequence Database (http://www.ebi.ac.uk/ena/
data/view/PRJEB7337). HLA ambiguities from the SBT




Full-length HLA-A, B, and C loci were contiguously
amplified using long-range PCR. These class I PCR pa-
rameters were optimized to minimize allele bias and in-
crease locus specificity. The full-length class II HLA-
DRB1 locus was contiguously amplified using modified
primers and PCR conditions to facilitate amplification of
all DRB1 alleles, ranging from 10.8-17.1 kb and reduce
co-amplification of other class II genes [22]. Representa-
tive purified long-range PCR amplicons from the four
loci of one sample are shown in Additional file 5.
Full-length multiplex sequencing
We used a novel method, MIT-NGS that combined
long-range PCR and Illumina MiSeq-based multiplex
Table 2 HLA ambiguities between SBT and MIT-NGS HLA
genotyping methods
Locus SBT Alleles in G group* MIT-NGS
A 23:01:01G 7 23:17 (2)
B 40:01:01G 17 40:01:02 (7)
07:05:01G 2 07:06 (3)
35:01:01G 18 35:01:23 (2)
C 07:01:01G 13 07:06 (8), 07:18 (4), 07:01:02 (1)
03:02:01G 10 03:02:02 (7)
12:02:01G 3 12:02:02 (7)
04:01:01G 20 04:82 (1)
15:05:01G 4 15:05:02 (1)
DRB1 14:01:01G 2 14:54 (6)
11:06:01G 2 11:129 (1)
The number of individuals with this allele is shown in parentheses.
*Number of ambiguous alleles defined by the G group (IMGT/HLA release 3.16.0).
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in a single run. Quality scores ≥Q30 for 88.9% of the
reads were obtained, with 91.7% of the 17.111 million
clusters passing the quality filter that eliminates reads
having more than one base call with chastity scores
of <0.6 in the first 25 cycles. Poor quality reads pre-
vented analyses of all loci for one of the 96 individuals.
Thus, of the initial 768 sequenced alleles (96 individuals ×
4 loci × 2 alleles) 760 were further analyzed for HLA geno-
types. Omixon was used to analyze the FASTQ files and
generate HLA typing calls. Sequence metrics from the
MiSeq-Omixon pipeline are summarized in Table 1.
HLA genotyping ambiguities
The HLA-SBT typing method generates genotypes based
solely on the highly polymorphic PBR defined by exons
2–3 for class I, and exon 2 for class II. HLA alleles that
share sequence identity over these regions but differ
elsewhere in the sequence are considered ambiguous al-
leles. HLA genotypes obtained by HLA-SBT were com-
pared to those from the novel MIT-NGS method
(Additional file 6). We identified 13 different ambiguous
HLA alleles, with 50 occurrences in 41 individuals, em-
phasizing the potential of full-length sequencing to en-
hance resolution and typing accuracies (Table 2).
Ambiguities were detected in at least one locus in 43.2%
(41 of 95) of sequenced individuals and 6.6% (50 of 760)
of typed alleles. Four of these individuals had ambigu-
ities at two or three different loci. The MIT-NGS
method was able to differentiate HLA-C*07:01:01G allele
into three allele subtypes, namely 07:06, 07:18, and
07:01:02. The most frequent SBT/MIT-NGS allele ambi-
guities at each locus were HLA-A*23:01:01G/23:17 (2 of 2);
HLA-B*40:01:01G/40:01:02 (7 of 12); HLA-C*07:01:01G/
07:06 (8 of 29), and HLA-DRB1*14:01:01G/14:54:01
(6 of 7). Importantly, 25 of the 50 ambiguities were due to
non-synonymous protein coding changes. All of the allele
ambiguities except one resulted from differences at one or
two polymorphic SNP positions. An exception was the
C*04:82 allele which had a 9 bp insertion relative to
*04:01:01 in exon 5 at position 970. The MIT-NGS methodTable 1 Summary of the NGS HLA Omixon software
sequencing metrics from the MiSeq run
Locus Average depth
of all exonsa
Allele ratiosb Detection <100%
of all exonsc
A 1311 (87.4-2580) 0.7-1.25 38 (96.2-99.9%)
B 1192 (104–2820) 0.78-1.24 112 (92.3-99.9%)
C 1527 (94–3570) 0.59-1.76 114 (98.8-99.9%)
DRB1 475 (26.8-1520) 0.35-3.02 5 (92.9-95.4%)
aAverage exonic sequence read depth per base pair.
bRatio of average sequence read coverage of alleles one and two.
cNumber of alleles with less than 100% sequence coverage.
The range in sequence coverage is indicated in parentheses.was able to resolve all HLA allele ambiguities that were
observed in the SBT method.HLA typing discordances
We evaluated concordance between the novel MIT-NGS
method and the SBT method for all 95 of the individuals
analyzed. The MIT-NGS and SBT genotype concordance
rates were 100% for HLA-A (190 of 190), 98.9% for
HLA-B (188 of 190), 100% for HLA-C (190 of 190), and
94.2% for HLA-DRB1 (179 of 190). These apparent dis-
cordances in 13 alleles were due to miscalls or ambigu-
ous allele combinations and are summarized in Table 3.
Closer examination of alignments using reference se-
quences from the IMGT/HLA database and the IGV
browser showed that the MIT-NGS calls were correct ra-
ther than the original SBT results. Seven discordances were
due to the mis-incorporation of a non-complementary base
of an SBT primer during PCR amplification. Six discor-
dances resulted from ambiguous allele combinations that
occurred when sequences of paired alleles shared respect-
ive group specific differentiating SNP(s) that could not be
differentiated by SBT and remained unphased.
The results reported above do not include four HLA-
DRB1 discordances that were not adequately detected by
MIT-NGS initially. These samples had allele dropout
relative to the SBT calls and were repeated using a
three-fold increase in the DRB1 amplicon concentration
ratio compared to the class I loci. The resulting calls
from MIT-NGS matched the HLA-SBT genotypes
(Additional file 7). Overall, the MIT-NGS method gener-
ated very high-resolution HLA typing for 95 individuals
and accurately genotyped 100% of the HLA class I and
DRB1 locus alleles.
Table 3 HLA discordances between SBT and MIT-NGS HLA
genotyping methods
Locus SBT MIT-NGS Classification
B 14:03/35:01:01G 14:02:01/35:08:01 (1) ambiguous allele
combination
DRB1 01:02:01/08:01:05 01:02:01/08:01:03 (1) nucleotide
mismatch
08:01:05/08:01:05 08:01:03/08:01:03 (1) nucleotide
mismatch
10:01:01/11:01:01G 10:01:01/11:01:02 (1) nucleotide
mismatch
03:01:01G/11:01:01G 03:01:01/11:01:02 (1) nucleotide
mismatch
11:01:01G/13:01:01G 11:01:02/13:01:01 (1) nucleotide
mismatch
11:01:01G/15:03:01G 11:01:02/15:03:01 (1) nucleotide
mismatch
13:01:01/14:07:01 13:02:01/14:54:01 (2) ambiguous allele
combination
Discordant alleles are highlighted in bold.
The number of individuals with a given genotype is indicated in parentheses.
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Successful HLA genotyping depends on robust amplifi-
cation strategies, high quality sequencing output, and ac-
curate sequence analysis algorithms. Recent reports have
demonstrated the feasibility of applying long-range PCR
based approaches to generate 6 or 8-digit HLA typing
using different NGS platforms [9,10]. The analysis process
ranged from direct local alignment searches of the IMGT/
HLA database for nearest matched alleles [9]; to local
alignment searches after phase conferring heterozygous
SNP mapping and alignment against hg19 human genome
reference sequences [10]. To further increase throughput,
target specificity, and cost effectiveness we developed a
novel genotyping method called MIT-NGS that uses
highly specific primer and PCR conditions to amplify full-
length HLA-A, B, C and DRB1 loci from 96 individuals.
Pooled amplicons from four loci of each individual were
tagged with the same unique index combination. This
multiplex individual tagging method enabled simultaneous
indexing of all 384 loci with 96 paired indices. All indexed
samples were then pooled and sequenced on a single run
of the Illumina MiSeq platform.
To decrease complexity associated with NGS sequence
analyses, FASTQ files from the MiSeq instrument were
directly analyzed by a commercially available NGS HLA
typing analysis software. Omixon has alignment algo-
rithms that map NGS short reads to allele sequences in
the IMGT/HLA database. Since many alleles in the data-
base lack intronic sequences, analysis that includes only
exonic sequences currently provides the most consistent
HLA typing results. Reads are mapped to multiple alleles
with limited mismatches, and the resulting allelecandidates are compared statistically for the depth and
evenness of coverage. Allele depth percentages were
greater than 25% for minor alleles of heterozygous
samples for all four loci, with the majority greater than
40% (Additional file 6). Average sequence read cover-
age percentages across exons for all samples were
greater than 90% (Additional file 8).
The SBT method targets the highly polymorphic PBR,
encoded by one or two exons, and relies on interpretation
of differences in chromatogram traces at putative SNP po-
sitions. In contrast, MIT-NGS generates genotypes from
full-length sequences encompassing all exons, based on al-
lele sequence availability in the IMGT/HLA database.
Short read pileups of each allele with corresponding reads
can be reviewed visually in the Omixon software facilitat-
ing quality checks and validation of alternate allele options
(Figure 1). Vast sequencing depth and coverage also en-
ables generation of high-resolution and phased genotypes.
In comparisons between the SBT and MIT-NGS methods,
50 ambiguous alleles were observed. MIT-NGS consist-
ently produced the higher resolution non-ambiguous
HLA allele calls, predominantly due to sequence coverage
of all polymorphic positions in regions not restricted to
the PBR. Further, half of all the ambiguous calls were due
to variation that impacted the HLA protein, highlighting
the importance of the MIT-NGS method. A recent study
demonstrating HLA typing using the NGS Illumina MiSeq
platform was limited to exons 2–3 and hence did not
address these ambiguities [8]. Enhanced resolution un-
ambiguous HLA typing is particularly relevant in solid
organ and hematopoietic stem cell transplantation
where closely related alleles may associate with very dif-
ferent outcomes [23,24].
The combined rates of concordance including alleles
ambiguously typed by SBT but resolved by MIT-NGS as
concordant for all four HLA loci between the two
methods was 98.3%. The remaining genotype discor-
dances between the MIT-NGS and SBT methods were
due to the accuracy of the MIT-NGS calls compared to
the SBT HLA typing. Even though HLA-SBT is the gold
standard for HLA-typing this method was susceptible to
undefined phasing as well as nucleotide misincorpora-
tions introduced by an HLA-DRB1 reverse primer in
exon 2. We established that the MIT-NGS method was
accurate because of its ability to phase as well as being
able to visualize the correct polymorphism with high se-
quence depth and coverage in key exons. In the initial
run of the MIT-NGS method, four miscalls occurred at
the DRB1 locus due to allelic imbalance and dropout.
Since the average class I and DRB1 amplicon sizes are ~5
and 17 kb, respectively, we increased the DRB1 amplicon
input by ~ three-fold to enable equimolar amplicon repre-
sentation for these samples. This approach corrected the
miscalls observed in the HLA-DRB1 loci and increased
Figure 1 Short read pile-ups of HLA sequences. A graphical representation of sequence read alignments for (A) HLA-A, (B) HLA-B, (C) HLA-C,
and (D) HLA-DRB1 paired alleles compiled by the Omixon software from MiSeq generated FASTQ files. Only exons are shown in this alignment
for simplicity.
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Overall this also improved the average coverage and depth
of all four loci (Additional file 7).
The ability of the MIT-NGS method to capture the ex-
tensive HLA diversity in different populations [25-27]
was highlighted by genotyping ethnically diverse individ-
uals. This method successfully genotyped 33 HLA-A, 55
HLA-B, 30 HLA-C and 41 HLA-DRB1 alleles from 95
individuals belonging to major ethnic groups including
Asian (47%), Caucasian (26%), and African (17%) ances-
try. Furthermore, this method was robust enough to
identify several alleles that were not detected by PCR-
SBT previously and were present at very low frequencies
such as, A*02:17:01, A*02:20:02, A*23:17, B*35:43:01,
B*39:08, C*02:10, C*04:52, C*04:82, C*07:18, DRB1*03:15,
DRB1*04:87 and DRB1*11:129. Other important chal-
lenges that need to be addressed for high-throughput
HLA genotyping include cost effectiveness, ease of setup,
hands-on laboratory time, and sequence analyses tools.
We have established that the laboratory costs associated
with the four loci multiplex MiSeq-based MIT-NGS HLA
typing method for 96 individuals are considerably less
than those incurred with SBT typing. Similarly, PCR setup
and downstream sequencing processes for the MIT-NGS
method are comparable to the SBT method, but less la-
borious and time consuming since sequencing reactions
are reduced due to multiplexing and pooling (Additional
file 9). Though we used commercially available software
for HLA sequence analyses, the MIT-NGS method is flex-
ible enough to be used with either in-house or other NGS
HLA typing software. Moreover, this multiplex method
can also be adapted to sequence other genes.Conclusions
The novel MIT-NGS method for HLA typing compris-
ing multiplex full-length HLA sequencing and analysis
proved to be an efficient and accurate tool for very high-
resolution HLA genotyping. Compared to the SBT
method, MIT-NGS concordantly called all HLA alleles
and was further able to clarify and resolve ambiguities.
This method can be used for research and with further
work we envisage that HLA typing by NGS will improve
transplantation matching, because of the increased reso-
lution demonstrated here. The current method types the
four most diverse HLA loci: HLA-A, B, C and DRB1.
With next-generation sequencing and analysis technolo-
gies improving rapidly it will be possible to expand the
multi-locus individual tagging multiplex approach de-
scribed here to other HLA class II loci and increase
throughput. The potential to genotype 96 samples for
four of the most variable HLA loci, at a cost comparable
to Sanger SBT methods but with the increased reso-
lution defined by NGS, is a major advance with clear
benefit to the HLA community. The ability of MIT-NGS
to accurately, robustly, efficiently, and cost effectively
genotype HLA across ethnically diverse populations has
important implications for disease studies, vaccine trials,
and transplantation science.Additional files
Additional file 1: HLA-DRB1 SBT amplification primers.
Additional file 2: HLA-DRB1 group specific primer combinations
and allele specificities.
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Additional file 4: Long-range amplification cycling parameters for
all four loci.
Additional file 5: Long-range PCR HLA amplicons.
Additional file 6: MIT-NGS allele calls and analysis metrics for 96
individuals.
Additional file 7: MIT-NGS allele calls and analysis metrics for the
initial DRB1 discordant samples.
Additional file 8: Average sequence read coverage percentage of
exons across HLA alleles.
Additional file 9: Comparison of the SBT and MIT-NGS HLA
genotyping laboratory methods.
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